Effects of FOXM1 inhibition and ionizing radiation on melanoma cells

Lee,Vivienne S.; McRobb,Lucinda S.; Moutrie,Vaughan; Santos,Estavam D.; Siu,Timothy L.

doi:10.3892/ol.2018.9482

Effects of FOXM1 inhibition and ionizing radiation on melanoma cells

Authors:
- Vivienne S. Lee
- Lucinda S. McRobb
- Vaughan Moutrie
- Estavam D. Santos
- Timothy L. Siu
View Affiliations

Affiliations: Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia, Genesis Cancer Care, Macquarie University Hospital, Sydney, NSW 2109, Australia
Published online on: September 21, 2018 https://doi.org/10.3892/ol.2018.9482
Pages: 6822-6830

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastatic melanoma can be highly refractory to conventional radiotherapy and chemotherapy but combinatorial‑targeted therapeutics are showing greater promise on improving treatment efficacy. Previous studies have shown that knockdown of Forkhead box M1 (FOXM1) can sensitize various tumor types to radiation‑induced cell death. The effect of combining radiation with a small molecule FOXM1 inhibitor, Siomycin A, on growth, death and migration of a metastatic melanoma cell line (SK‑MEL‑28) that overexpresses this pleiotropic cell cycle regulator was investigated. Siomycin A (SIOA) was found to be a strong inducer of apoptosis, and inhibitor of proliferation and migration in a scratch wound assay in this cell line. Induction of apoptosis occurred at concentrations >1 µM in association with reductions in the constitutive FOXM1 and anti‑apoptotic B‑cell lymphoma 2 protein levels found in these cells. Single doses of ionizing radiation (0‑40 Gy) delivered by linear accelerator caused inhibition of growth and migration without significant induction of cell death. Pretreatment with SIOA did not increase the sensitivity of this melanoma cell line to radiation as observed in other tumor types. These data confirm that as a single agent, SIOA is an effective inducer of cell death and inhibitor of migration in metastatic melanoma cells expressing constitutive FOXM1. In combination with radiation, SIOA pre‑treatment, however, may not be of added benefit.

View Figures

View References

1	Khan MK, Khan N, Almasan A and Macklis R: Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther. 4:137–148. 2011. View Article : Google Scholar : PubMed/NCBI
2	Bullard DE, Cox EB and Seigler HF: Central nervous system metastases in malignant melanoma. Neurosurgery. 8:26–30. 1981. View Article : Google Scholar : PubMed/NCBI
3	Myatt SS and Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859. 2007. View Article : Google Scholar : PubMed/NCBI
4	Wang Z, Ahmad A, Li Y, Banerjee S, Kong D and Sarkar FH: Forkhead box M1 transcription factor: A novel target for cancer therapy. Cancer Treat Rev. 36:151–156. 2010. View Article : Google Scholar : PubMed/NCBI
5	Xu XS, Miao RC, Wan Y, Zhang LQ, Qu K and Liu C: FoxM1 as a novel therapeutic target for cancer drug therapy. Asian Pac J Cancer Prev. 16:23–29. 2015. View Article : Google Scholar : PubMed/NCBI
6	Wierstra I: FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res. 119:191–419. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ito T, Kohashi K, Yamada Y, Maekawa A, Kuda M, Furue M and Oda Y: Prognostic significance of forkhead box M1 (FoxM1) expression and antitumour effect of FoxM1 inhibition in melanoma. Histopathology. 69:63–71. 2016. View Article : Google Scholar : PubMed/NCBI
8	Miyashita A, Fukushima S, Nakahara S, Yamashita J, Tokuzumi A, Aoi J, Ichihara A, Kanemaru H, Jinnin M and Ihn H: Investigation of FOXM1 as a potential new target for melanoma. PLoS One. 10:e01442412015. View Article : Google Scholar : PubMed/NCBI
9	Kruiswijk F, Hasenfuss SC, Sivapatham R, Baar MP, Putavet D, Naipal KA, van den Broek NJ, Kruit W, van der Spek PJ, van Gent DC, et al: Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. Oncogene. 35:2166–2177. 2016. View Article : Google Scholar : PubMed/NCBI
10	Bhat UG, Zipfel PA, Tyler DS and Gartel AL: Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle. 7:1851–1855. 2008. View Article : Google Scholar : PubMed/NCBI
11	Maachani UB, Shankavaram U, Kramp T, Tofilon PJ, Camphausen K and Tandle AT: FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells. Oncotarget. 7:77365–77377. 2016. View Article : Google Scholar : PubMed/NCBI
12	Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford RF and Rizos H: Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol. 8:544–554. 2014. View Article : Google Scholar : PubMed/NCBI
13	Carlino MS, Gowrishankar K, Saunders CA, Pupo GM, Snoyman S, Zhang XD, Saw R, Becker TM, Kefford RF, Long GV and Rizos H: Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther. 12:1332–1342. 2013. View Article : Google Scholar : PubMed/NCBI
14	Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, et al: Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 5:56942014. View Article : Google Scholar : PubMed/NCBI
15	Zhang XD, Franco A, Myers K, Gray C, Nguyen T and Hersey P: Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 59:2747–2753. 1999.PubMed/NCBI
16	Pupo GM, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, Johansson P, Hayward NK, Kefford RF, Scolyer RA, et al: Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomark Res. 5:172017. View Article : Google Scholar : PubMed/NCBI
17	Halasi M and Gartel AL: Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage. PLoS One. 7:e317612012. View Article : Google Scholar : PubMed/NCBI
18	Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S and Bold RJ: Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol. 56:46–54. 2005. View Article : Google Scholar : PubMed/NCBI
19	Almond JB and Cohen GM: The proteasome: A novel target for cancer chemotherapy. Leukemia. 16:433–443. 2002. View Article : Google Scholar : PubMed/NCBI
20	Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, Tyner AL, Lau LF, Costa RH and Raychaudhuri P: FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J. 28:2908–2918. 2009. View Article : Google Scholar : PubMed/NCBI
21	Halasi M, Pandit B, Wang M, Nogueira V, Hay N and Gartel AL: Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth. Am J Pathol. 183:257–265. 2013. View Article : Google Scholar : PubMed/NCBI
22	Kinugasa H, Whelan KA, Tanaka K, Natsuizaka M, Long A, Guo A, Chang S, Kagawa S, Srinivasan S, Guha M, et al: Mitochondrial SOD2 regulates epithelial-mesenchymal transition and cell populations defined by differential CD44 expression. Oncogene. 34:5229–5239. 2015. View Article : Google Scholar : PubMed/NCBI
23	Hosoki A, Yonekura S, Zhao QL, Wei ZL, Takasaki I, Tabuchi Y, Wang LL, Hasuike S, Nomura T, Tachibana A, et al: Mitochondria-targeted superoxide dismutase (SOD2) regulates radiation resistance and radiation stress response in HeLa cells. J Radiat Res. 53:58–71. 2012. View Article : Google Scholar : PubMed/NCBI
24	Sun Y, St Clair DK, Fang F, Warren GW, Rangnekar VM, Crooks PA and St Clair WH: The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther. 6:2477–2486. 2007. View Article : Google Scholar : PubMed/NCBI
25	Benlloch M, Mena S, Ferrer P, Obrador E, Asensi M, Pellicer JA, Carretero J, Ortega A and Estrela JM: Bcl-2 and Mn-SOD antisense oligodeoxynucleotides and a glutamine-enriched diet facilitate elimination of highly resistant B16 melanoma cells by tumor necrosis factor-alpha and chemotherapy. J Biol Chem. 281:69–79. 2006. View Article : Google Scholar : PubMed/NCBI
26	Lee Y, Kim KH, Kim DG, Cho HJ, Kim Y, Rheey J, Shin K, Seo YJ, Choi YS, Lee JI, et al: FoxM1 promotes stemness and radio-resistance of glioblastoma by regulating the master stem cell regulator Sox2. PLoS One. 10:e01377032015. View Article : Google Scholar : PubMed/NCBI
27	Kurland JF and Meyn RE: Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells. Int J Cancer. 96:327–333. 2001. View Article : Google Scholar : PubMed/NCBI
28	Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP and Hersey P: Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res. 14:1659–1668. 2008. View Article : Google Scholar : PubMed/NCBI
29	Buch K, Peters T, Nawroth T, Sänger M, Schmidberger H and Langguth P: Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay-a comparative study. Radiat Oncol. 7:12012. View Article : Google Scholar : PubMed/NCBI